Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Exclusion Criteria

• •A prior history of Myocardial Infarction (MI)
• •Subjects who have received any thrombolytic therapy during the current hospital admission
• •Severe Heart Failure or cardiogenic shock (Killip class 3 or 4) by history or present at the time of screening
• •Subjects with a plasma glucose \>400 mg/dL or diabetic ketoacidosis (DKA)
• •History of Type 1 diabetes
• •Active bleeding
• •Active malignancy, chronic or other medical conditions likely to result in death over the next one year
• •Recent hypotension requiring inotropic support in the past 30 days
• •Participation in another clinical research study in the past 30 days
• •Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method)
• •Unwilling to give informed consent
• •Subjects directly involved in the conduct of the study
• •Known hypersensitivity to insulin glargine or glulisine
• •Contraindication to MRI: a)Intracranial aneurysm clips (Unless the investigator is certain that it is made of non-ferromagnetic material such as titanium)b)Intra-orbital metal fragments c)Any electrically, magnetically or mechanically activated implants (including cardiac pacemakers, biostimulators, neurostimulators, cochlear implants, and hearing aids) d)Warning about Gadolinium-based contrast agents (GBCAs) Exposure to GBCAs increases the risk for nephrogenic systemic fibrosis (NSF). Therefore the following subjects should be excluded from the trial based on a history and/or laboratory tests:
• •* acute or chronic severe renal insufficiency (glomerular filtration rate \<30 mL/min/1.73m2), as calculated by the MDRD (Modification of diet in Renal Disease) equation, or
• •* acute renal insufficiency of any severity
• •Subjects with blood pressure \> or = to 200/110 mmHg at time of randomization
• •Subjects with a high degree of non-transient AV (Atrio-Ventricular) block
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.